High Growth Tech Stocks To Watch In September 2024
In This Article:
In the last week, the Australian market has stayed flat while the Real Estate sector gained 3.3%, and over the past 12 months, it has risen by 11% with earnings forecasted to grow by 12% annually. In this context, identifying high-growth tech stocks that can capitalize on these favorable conditions is crucial for investors looking to maximize their returns in September 2024.
Top 10 High Growth Tech Companies In Australia
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Clinuvel Pharmaceuticals | 22.41% | 27.42% | ★★★★★★ |
| Pureprofile | 14.94% | 80.73% | ★★★★★☆ |
| AVA Risk Group | 32.56% | 118.83% | ★★★★★★ |
| ImExHS | 20.47% | 111.20% | ★★★★★★ |
| DUG Technology | 10.90% | 32.21% | ★★★★★☆ |
| Pointerra | 56.62% | 126.45% | ★★★★★★ |
| Careteq | 34.13% | 126.60% | ★★★★★☆ |
| Wrkr | 36.31% | 100.29% | ★★★★★★ |
| Adveritas | 57.98% | 144.21% | ★★★★★★ |
| SiteMinder | 19.39% | 60.31% | ★★★★★☆ |
Click here to see the full list of 61 stocks from our ASX High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Nuix
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Nuix Limited provides investigative analytics and intelligence software solutions across the Asia Pacific, the Americas, Europe, the Middle East, and Africa with a market cap of A$1.79 billion.
Operations: Nuix generates revenue primarily from its Software & Programming segment, which accounted for A$220.62 million. The company focuses on delivering investigative analytics and intelligence software solutions globally.
Nuix has shown impressive growth, reporting a 20.90% increase in annual revenue to AUD 220.62 million and achieving profitability with a net income of AUD 5.03 million for the year ending June 30, 2024. Their strategic partnership with Veritone enhances their eDiscovery and compliance solutions, leveraging AI technology to handle complex data sets efficiently. The company has also focused on innovation, allocating significant resources to R&D expenditures which totaled AUD 15 million this fiscal year, representing a commitment to continuous improvement and technological advancement in the software industry.
-
Get an in-depth perspective on Nuix's performance by reading our health report here.
-
Gain insights into Nuix's past trends and performance with our Past report.
Pro Medicus
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system (RIS) software to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe with a market cap of A$16.40 billion.
Operations: Pro Medicus Limited generates revenue primarily from producing integrated software applications for the healthcare industry, amounting to A$161.50 million. The company's operations span Australia, North America, and Europe.